Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,599,200 papers from all fields of science
Search
Sign In
Create Free Account
7-ethyl-10-hydroxycamptothecin glucuronide
Known as:
SN-38 glucuronide
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Camptothecin
Glucuronides
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
F. Innocenti
,
D. Kroetz
,
+7 authors
M. Ratain
Journal of clinical oncology : official journal…
2009
Corpus ID: 29279981
PURPOSE We aim to identify genetic variation, in addition to the UGT1A1*28 polymorphism, that can explain the variability in…
Expand
Highly Cited
2006
Highly Cited
2006
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancer
K. Araki
,
Ken-Ichi Fujita
,
+7 authors
Y. Sasaki
Cancer science
2006
Corpus ID: 25092316
Pharmacogenetic testing for UDP‐glucuronosyltransferase (UGT) 1A1*28, a promoter variant of the UGT1A1 gene, is now carried out…
Expand
Highly Cited
2004
Highly Cited
2004
UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer
K. Sai
,
M. Saeki
,
+17 authors
N. Saijo
Clinical pharmacology and therapeutics
2004
Corpus ID: 44325361
Highly Cited
2002
Highly Cited
2002
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
L. Iyer
,
S. Das
,
+7 authors
M. Ratain
The Pharmacogenomics Journal
2002
Corpus ID: 20140154
The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically…
Expand
Highly Cited
2002
Highly Cited
2002
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice
L. Iyer
,
J. Ramírez
,
+4 authors
U. Mayer
Cancer Chemotherapy and Pharmacology
2002
Corpus ID: 13144916
Abstract.Purpose: The extensive and unpredictable biliary excretion of CPT-11 and its metabolites, SN-38 and SN-38 glucuronide…
Expand
Highly Cited
2002
Highly Cited
2002
The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
M. Horikawa
,
Y. Kato
,
C. Tyson
,
Y. Sugiyama
Drug metabolism and pharmacokinetics
2002
Corpus ID: 28004804
Irinotecan hydrochloride (CPT-11) is an anticancer agent with unpredictable bouts of diarrhea as a dose-limiting toxic side…
Expand
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
J. Slatter
,
L. Schaaf
,
+11 authors
R. S. Lord
Drug metabolism and disposition: the biological…
2000
Corpus ID: 280408
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100…
Expand
Highly Cited
1999
Highly Cited
1999
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
H. Friedman
,
W. Petros
,
+20 authors
L. Miller
Journal of clinical oncology : official journal…
1999
Corpus ID: 37919166
PURPOSE To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo…
Expand
Highly Cited
1998
Highly Cited
1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
L. Saltz
,
D. Spriggs
,
+12 authors
D. Kelsen
Journal of clinical oncology : official journal…
1998
Corpus ID: 11897939
PURPOSE In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these…
Expand
Highly Cited
1996
Highly Cited
1996
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and…
P. Canal
,
C. Gay
,
+7 authors
A. Mathieu-Boué
Journal of clinical oncology : official journal…
1996
Corpus ID: 32631422
PURPOSE A pharmacokinetic study was performed during a phase II clinical trial of irinotecan (CPT-11) to confirm the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE